05:25 AM EDT, 10/12/2026 (MT Newswires) -- UBS Global Research expects Reckitt Benckiser Group (RKT.L) to report an increase in third-quarter sales when the company releases its latest quarterly trading update on Oct. 27. The UK-based consumer goods group's like-for-like sales are projected to rise 3.7% year over year to 3.29 billion pounds sterling in the quarter, against the Visible Alpha consensus of 3.6%, according to a sector preview note. On a reported basis, UBS forecasts a 5.2% annual growth in sales. "Within this, we model Q3 LFL of +4.2% for Core Reckitt (VA cons +4.0%), consistent with the +4.2% posted in Q2. That said, we anticipate growth to be more broad-based in Q3 as Europe should improve sequentially (from -1.5% in Q2 to flat in Q3), North America is likely to normalise as Reckitt laps last year's shelf reset benefit in Cough & Cold (UBSe +1.0% down from +2.8% in Q2) and Emerging Markets to remain in HSD territory (+9.5% in Q3, was +9.4% in Q2)," the research firm said. "This implies Reckitt needs to deliver 6+% in Q4 to reach the bottom end of its 4-5% guidance range, which RKT is confident it can achieve, led by easier Europe comps, China Durex launches, and a modest uplift in Cough & Cold incidence," UBS added. For full-year 2026, the research firm anticipates like-for-like sales growth to come in at 3.6%, compared with the consensus of 3.5%. Reckitt's stock is rated buy at UBS.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.